

Image 6P1614

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
0994.00133

In Re Application Of: Katti, et al

DEC 22 2003

Serial No.
10/019,192Filing Date
06/20/2002Examiner
Krass, Frederick, F.Group Art Unit
1614

Title: GOLD CONTAINING CHEMOTHERAPEUTIC AGENTS

Address to:

Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

1. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☒ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☒ the fee set forth in 37 CFR 1.17(p).

12/31/2003 DTESSEM1 00000016 10019192

01 FC:1806

180.00 OP

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
0994.00133

In Re Application: *1 P. Kanti, et al.*

Serial No.
10/019,1

Filing Date
06/20/2002

Examiner
Krass, Frederick, F.

Group Art Unit
1614

GOLD CONTAINING CHEMOTHERAPEUTIC AGENTS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☒ A check in the amount of **\$180.00** is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. _____ as described below. A duplicate copy of this sheet is enclosed:
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited **December 19, 2003** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Marie M. DeWitt

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated: _____

CC:



MANUAL OF PATENT EXAMINING PROCEDURE

PTO/SB/08 (2-92)
Sheet 1 of 1

PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Docket Number (Optional) 0994.00133		Application Number 10/019,192	
				Applicant Kattesh V. Katti, et al.			
				Filing Date 06/20/02		Group Art Unit 1614	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLAS S	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS							
	DOCKET NUMBER	DATE	COUNTRY	CLAS S	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS <i>(Including Author, Title, Date Pertinent Pages, Etc.)</i>	
	Berglof, F.E., et al., "Auranofin: an Oral Chrysotherapeutic Agent for the Treatment of Rheumatoid Arthritis," <i>J. Rheumatol.</i> , 5, 68 (1978).
	Berning, D.E., et al., "In Vitro and In Vivo Characterization of a ^{99m} Tc Complex with Tris(hydroxymethyl)phosphine (THP), Hyroxymethyl bis(phosphines) and their palladium(II) and platinum(II) complexes formed via biphasic reactions. Crystal structure of [Pd(HOH ₂ C) ₂ PC ₆ H ₄ P(CH ₂ OH) ₂] ₂ CL ₂ Nucl. <i>Med. Biol.</i> , 23, 617 (1996).
	Fricker, S.P., "Medicinal chemistry and pharmacology of gold compounds," <i>Transition Met. Chem.</i> , 21, 377 (1996).
	Katti, K.V., "Recent advances in the chemistry of water-soluble phosphines - Catalytic and biomedical aspects," <i>Curr. Sci.</i> , 70, 219 (1996).
	Mirabelli, C.K., et al., "Evaluation of the <i>In Vivo</i> Antitumor Activity and <i>In Vitro</i> Cytotoxic Properties of Auranofin, a Coordinated Gold Compound, in Murine Tumor Models," <i>Cancer Res.</i> , 45, 32 (1985).
	Reddy, V.S., et al., "Chemistry in Environmentally Benign Media," <i>Inorg. Chem.</i> , 35, 1753 (1996).
	Reddy, V.S., et al., <i>Inorg. Chem. Acta.</i> , 240, 367 (1995).
	Reddy, V.S., et al., <i>J. Chem. Soc. Dalton Trans.</i> , 1301 (1996).
	Schubiger, P.A., et al., "Vehicles, Chelators, and Radionuclides: Choosing the "Building Blocks" of an Effective Therapeutic Radioimmunoconjugate," <i>Bioconjugate Chem.</i> , 7, 165 (1996).
	Shi, J.C., et al., "Chiral Phosphine Ligands Derived from Sugars," <i>Inorg. Chem.</i> , 35, 2742 (1996).
	Simon, et al., "Screening Trial with the Coordinated Gold Compound Auranofin Using Mouse Lymphocytic Leukemia P388," <i>Cancer Res.</i> , 41, 94 (1981).
	Volkert, W.A., et al., "Therapeutic Radionuclides: Production and Decay Property Considerations," <i>J. Nucl. Med.</i> , 32, 174 (1991).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE